Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Director | April 07, 2026 | April 09, 2026 |
| Twin Vee PowerCats, Co.VEEE · Entity 8235 | Director | March 19, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,213 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 9,185 · Balance 9,213 F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectOwned by Mr. Schuyler's wife, Carolyn M. Schuyler | 4 |
Reported balance
Holding disclosure · report date 2026-04-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4 |
| Common StockSEC Table I · non-derivative | IndirectOwned by MVA 151 Investors, LLC | 230 |
Reported balance
Holding disclosure · report date 2026-04-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 230 F2: Mr. Schuyler has control over MVA 151 Investors, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.
F2: Mr. Schuyler has control over MVA 151 Investors, LLC.
Twin Vee PowerCats, Co.
Report date March 19, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 31,252 |
Reported balance
After 2026-03-19 transaction · row 1
1 source rowRow 1 · 2026-03-19 · Purchase · Acquired 25,000 · Balance 31,252 F1: Open market purchase of shares in accordance with Issuer's trading policies. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase of shares in accordance with Issuer's trading policies.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forza X1, Inc.
Report date November 26, 2024 · Filed November 26, 2024
Section 16 reporting ended · disclosed 2024-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-26 transaction · row 1
1 source rowRow 1 · 2024-11-26 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Disposed of pursuant to the merger (the "Merger") of Twin Vee Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Twin Vee PowerCats Co., a Delaware corporation ("Twin Vee"), into Forza X1, Inc. ("Forza"), in exchange for 61,166 shares of Twin Vee common stock. Each share of Forza common stock was exchanged for 0.611666275 shares of Twin Vee common stock on the effective date of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2032-09-01 | Direct | 0 |
Reported balance
After 2024-11-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-26 · Disposition to issuer · Disposed 5,500 · Balance 0 F2: Consists of options to purchase shares of common stock that are fully vested and exercisable for a period of ten years from the date of grant, commencing on September 1, 2022. F3: This option was assumed by Twin Vee in the Merger and replaced with an option to purchase 3,364 shares of Twin Vee common stock for $8.17 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the merger (the "Merger") of Twin Vee Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Twin Vee PowerCats Co., a Delaware corporation ("Twin Vee"), into Forza X1, Inc. ("Forza"), in exchange for 61,166 shares of Twin Vee common stock. Each share of Forza common stock was exchanged for 0.611666275 shares of Twin Vee common stock on the effective date of the Merger.
F2: Consists of options to purchase shares of common stock that are fully vested and exercisable for a period of ten years from the date of grant, commencing on September 1, 2022.
F3: This option was assumed by Twin Vee in the Merger and replaced with an option to purchase 3,364 shares of Twin Vee common stock for $8.17 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 113,800 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 10 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by MVA 151 Investors, LLC Disclosed balance after: 113,800 Underlying: Common Stock · 162,200 shares Expires 2023-07-31 F3 · price: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F3 · derivative.underlying: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F6 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseWarrant to purchase common stock · Derivative | 90,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 9 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,461 Underlying: Common Stock · 90,000 shares Expires 2023-07-31 F7 · shares: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F7 · price: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 120,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 8 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,461 Underlying: Common Stock · 120,000 shares Expires 2023-07-31 F2 · price: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F2 · derivative.underlying: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionWarrant to purchase common stock · Derivative | 82,461 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 7 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,461 Underlying: Common Stock · 82,461 shares Expires 2023-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionConvertible Note · Derivative | 82,461 | Not disclosed Strike: $0.44 | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 6 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.exercise_date: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.expiration_date: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 113,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 4 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by MVA 151 Investors, LLC Disclosed balance after: 113,800 F3 · shares: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F3 · price: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F6 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 90,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 3 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,390 F7 · shares: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F7 · price: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 120,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 2 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,390 F2 · shares: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F2 · price: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionCommon Stock | 82,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 1 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · price: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 192,600 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 8 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by MVA 151 Investors, LLC Disclosed balance after: 192,600 Underlying: Units · 385,200 shares Expires 2023-07-31 F4 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 units was received by MVA 151 Investors LLC upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 385,200 shares. F4 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 units was received by MVA 151 Investors LLC upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 385,200 shares. F5 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 89,600 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 7 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,600 Underlying: Units · 179,200 shares Expires 2023-07-31 F3 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect the purchase 89,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 179,200 shares. F3 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect the purchase 89,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 179,200 shares. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 192,600 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 6 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by MVA 151 Investors, LLC Disclosed balance after: 192,600 Underlying: Common Stock · 192,200 shares Expires 2023-07-31 F2 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F2 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F5 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseWarrant to purchase common stock · Derivative | 90,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 5 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2023-07-31 F6 · shares: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F6 · price: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 89,600 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 4 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,600 Underlying: Common Stock · 89,600 shares Expires 2023-07-31 F1 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F1 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 144,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · nonDerivative · entry 3 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by MVA 151 Investors, LLC Disclosed balance after: 144,200 F2 · shares: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F2 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F6 · ownership.nature: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 90,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · nonDerivative · entry 2 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,990 F6 · shares: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F6 · price: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 89,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-039338 · ownership.xml · nonDerivative · entry 1 Schuyler Kevin · CIK 0001718094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,990 F1 · shares: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F1 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.